Welcome to our dedicated page for Bioxcel Therapeutics SEC filings (Ticker: BTAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with clinical statistics, FDA correspondence, and AI R&D costs can feel like an extra research project. BioXcel Therapeutics’ documents are no exception—each 10-K details multi-arm trials for BXCL501, while 8-Ks often announce pivotal data read-outs or feedback from the FDA. If you have ever opened one of these reports searching for cash-runway figures or dosing-cohort results, you know the challenge.
Stock Titan solves this by pairing every BioXcel Therapeutics SEC filing with AI-powered summaries that translate technical language into plain English. Need the highlights from the latest BioXcel Therapeutics quarterly earnings report 10-Q filing? Our tool flags R&D spend, enrollment updates, and liquidity in seconds. Looking for BioXcel Therapeutics insider trading Form 4 transactions? Real-time alerts show you exactly when executives buy or sell stock, giving context around upcoming trial milestones.
All core forms are covered and continuously updated from EDGAR:
- 10-K and 10-Q for pipeline progress, AI-development costs, and risk factors—BioXcel Therapeutics annual report 10-K simplified
- 8-K material events like interim efficacy data—BioXcel Therapeutics 8-K material events explained
- DEF 14A proxy statements outlining leadership incentives and BioXcel Therapeutics proxy statement executive compensation
- Form 4 filings with BioXcel Therapeutics executive stock transactions Form 4 shown in real time
Whether you are benchmarking trial timelines, gauging insider confidence, or simply understanding BioXcel Therapeutics SEC documents with AI, our platform trims hours off your research. Open any filing, skim the concise AI analysis, and move straight to decision-making.
BioXcel Therapeutics (BTAI) – Insider Equity Grant
Chief Scientific Officer Frank Yocca filed a Form 4 on 08/05/2025 reporting the grant of 9,000 restricted stock units (RSUs) on 08/01/2025. Each RSU converts into one common share at no cost. The award vests 100 % within 30 days after nine months from the grant date, contingent on continued employment. Following the transaction, Yocca beneficially owns 9,000 derivative securities representing future common shares, all held directly. No shares were sold or disposed of, and no other equity transactions were reported.
The filing reflects routine executive compensation; the size of the award is immaterial relative to the company’s public float and does not meaningfully alter insider ownership or share-count dilution.
BioXcel Therapeutics (BTAI) filed an 8-K to disclose completion of the “last-patient-last-visit” milestone in its SERENITY At-Home pivotal Phase 3 safety trial of BXCL501 120 mcg for the acute treatment of agitation in bipolar disorder and schizophrenia.
- Randomized, double-blind, placebo-controlled design; >200 patients treated across 22 U.S. sites, with no site >11 % of enrollment.
- Patient mix was balanced between the two indications and the “vast majority” completed the 12-week study.
- >2,200 agitation episodes were captured, providing a sizable safety data set.
- Top-line results are expected later this month; management reiterates plans for a subsequent sNDA submission.
No financial metrics were provided. The filing consists mainly of forward-looking statements outlining regulatory intentions and associated risks.
BioXcel Therapeutics (BTAI) filed an 8-K announcing it has submitted a pre-supplemental NDA (pre-sNDA) package to the FDA seeking to expand IGALMI’s label to cover at-home treatment of acute agitation in schizophrenia or bipolar disorders. The FDA has scheduled the pre-sNDA meeting for 20 Aug 2025; BioXcel aims to confirm alignment on data requirements and formatting before filing the full sNDA. Management also intends to reconfirm guidance from a 6 Mar 2024 Type C meeting, in which the FDA deemed the company’s development plan a reasonable path to support the proposed 120 mcg BXCL501 outpatient indication.
No financial metrics were disclosed. The filing consists primarily of regulatory updates and forward-looking statements reminding investors of associated risks. Successful FDA agreement could open a materially larger market by allowing IGALMI to be self-administered outside clinical settings, but approval is still contingent on future FDA review.
FAQ
What is the current stock price of Bioxcel Therapeutics (BTAI)?
What is the market cap of Bioxcel Therapeutics (BTAI)?
